|Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the …|
BJ Edwards, AD Bunta, J Lane, C Odvina, DS Rao, DW Raisch, ...
The Journal of bone and joint surgery. American volume 95 (4), 297, 2013
|Life-threatening dermatologic adverse events in oncology|
AC Rosen, Y Balagula, DW Raisch, V Garg, B Nardone, N Larsen, ...
Anti-cancer drugs 25 (2), 225, 2014
|Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the …|
DW Raisch, V Garg, R Arabyat, X Shen, BJ Edwards, FH Miller, JM McKoy, ...
Expert opinion on drug safety 13 (1), 15-23, 2014
|Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting|
J Schmier, K Ogden, N Nickman, MT Halpern, M Cifaldi, A Ganguli, Y Bao, ...
Clinical therapeutics 39 (8), 1600-1617, 2017
|Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study|
F Van den Bosch, AJK Ostor, S Wassenberg, N Chen, C Wang, V Garg, ...
Rheumatology and therapy 4, 85-96, 2017
|Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication|
DW Raisch, W Campbell, V Garg, ZP Qureshi, PB Bookstaver, LAB Norris, ...
Expert opinion on drug safety 10 (4), 521-528, 2011
|Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study|
D Aletaha, AJ Epstein, M Skup, P Zueger, V Garg, R Panaccione
Advances in therapy 36, 1672-1683, 2019
|Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review|
Y Liu, M Yang, V Garg, EQ Wu, J Wang, M Skup
Advances in Therapy 36, 1851-1877, 2019
|Noninsulin pharmacological management of type 1 diabetes mellitus|
Indian journal of endocrinology and metabolism 15 (Suppl1), S5-S11, 2011
|Use of number needed to treat in cost-effectiveness analyses|
V Garg, X Shen, Y Cheng, JJ Nawarskas, DW Raisch
Annals of Pharmacotherapy 47 (3), 380-387, 2013
|Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States|
ZP Qureshi, LA Norris, O Sartor, JM McKoy, J Armstrong, DW Raisch, ...
Journal of Oncology Practice 8 (2), 84-90, 2012
|Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis|
V Garg, DW Raisch, JP Selig, TA Thompson
Prostate Cancer and Prostatic Diseases 16 (2), 193-203, 2013
|A literature review of cost–effectiveness analyses of prostate-specific antigen test in prostate cancer screening|
V Garg, NY Gu, ME Borrego, DW Raisch
Expert review of pharmacoeconomics & outcomes research 13 (3), 327-342, 2013
|Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis|
E Murray, A Ellis, Y Butylkova, M Skup, J Kalabic, V Garg
Journal of comparative effectiveness research 7 (10), 959-974, 2018
|Real-world effectiveness of biologic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis after etanercept discontinuation in the United Kingdom …|
N Li, KA Betts, AJ Messali, M Skup, V Garg
Clinical Therapeutics 39 (8), 1618-1627, 2017
|Long-term effectiveness of adalimumab in patients with rheumatoid arthritis: an observational analysis from the Corrona rheumatoid arthritis registry|
DA Pappas, JM Kremer, J Griffith, G Reed, B Salim, C Karki, V Garg
Rheumatology and therapy 4, 375-389, 2017
|Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis …|
D Aletaha, SJ Snedecor, V Ektare, M Xue, Y Bao, V Garg
ClinicoEconomics and Outcomes Research, 451-458, 2017
|Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results …|
GS Kaeley, DK MacCarter, JR Goyal, S Liu, K Chen, J Griffith, H Kupper, ...
Rheumatology and Therapy 5, 123-134, 2018
|Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs|
V Garg, DW Raisch, JM McKoy, SM Trifilio, J Holbrook, BJ Edwards, ...
Expert opinion on drug safety 12 (3), 299-307, 2013
|A Matching-adjusted indirect comparison of upadacitinib versus tofacitinib in adults with moderate-to-severe rheumatoid arthritis|
CJ Edwards, R Sawant, V Garg, EX Du, A Friedman, KA Betts
Rheumatology and Therapy 8, 167-181, 2021